These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

505 related items for PubMed ID: 15642076

  • 1. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W.
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [Abstract] [Full Text] [Related]

  • 2. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
    Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J.
    Diabet Med; 2007 Jan; 24(1):27-34. PubMed ID: 17227321
    [Abstract] [Full Text] [Related]

  • 3. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M.
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [Abstract] [Full Text] [Related]

  • 4. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.
    Raslová K, Bogoev M, Raz I, Leth G, Gall MA, Hâncu N.
    Diabetes Res Clin Pract; 2004 Nov; 66(2):193-201. PubMed ID: 15533587
    [Abstract] [Full Text] [Related]

  • 5. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study.
    Dornhorst A, Lüddeke HJ, Sreenan S, Kozlovski P, Hansen JB, Looij BJ, Meneghini L, PREDICTIVE Study Group.
    Int J Clin Pract; 2008 Apr; 62(4):659-65. PubMed ID: 18324957
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort.
    Dornhorst A, Lüddeke HJ, Sreenan S, Koenen C, Hansen JB, Tsur A, Landstedt-Hallin L.
    Int J Clin Pract; 2007 Mar; 61(3):523-8. PubMed ID: 17313628
    [Abstract] [Full Text] [Related]

  • 7. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.
    Ligthelm RJ, Mouritzen U, Lynggaard H, Landin-Olsson M, Fox C, le Devehat C, Romero E, Liebl A.
    Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):511-9. PubMed ID: 17115349
    [Abstract] [Full Text] [Related]

  • 8. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K, Dornhorst A, Sreenan S.
    Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
    [Abstract] [Full Text] [Related]

  • 9. Combination-therapy with bedtime nph insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes.
    Olsson PO, Lindström T.
    Diabetes Metab; 2002 Sep; 28(4 Pt 1):272-7. PubMed ID: 12442064
    [Abstract] [Full Text] [Related]

  • 10. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.
    Meneghini L, Koenen C, Weng W, Selam JL.
    Diabetes Obes Metab; 2007 Nov; 9(6):902-13. PubMed ID: 17924873
    [Abstract] [Full Text] [Related]

  • 11. Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins.
    Arutchelvam V, Heise T, Dellweg S, Elbroend B, Minns I, Home PD.
    Diabet Med; 2009 Oct; 26(10):1027-32. PubMed ID: 19900235
    [Abstract] [Full Text] [Related]

  • 12. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs.
    Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA, Orals Plus Apidra and LANTUS (OPAL) study group.
    Diabetes Obes Metab; 2008 Dec; 10(12):1178-85. PubMed ID: 19040645
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials.
    Bazzano LA, Lee LJ, Shi L, Reynolds K, Jackson JA, Fonseca V.
    Diabet Med; 2008 Aug; 25(8):924-32. PubMed ID: 18959605
    [Abstract] [Full Text] [Related]

  • 14. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
    Ceriello A, Del Prato S, Bue-Valleskey J, Beattie S, Gates J, de la Peña A, Malone J.
    J Diabetes Complications; 2007 Aug; 21(1):20-7. PubMed ID: 17189870
    [Abstract] [Full Text] [Related]

  • 15. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
    Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T.
    Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
    [Abstract] [Full Text] [Related]

  • 16. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [Abstract] [Full Text] [Related]

  • 17. [Postprandial glycemic control using insulin aspart with NPH in inadequately controlled diabetics].
    Gao Y, Pan CY, Zou DJ, Xu ZR, Liu XM, Guo XH.
    Zhonghua Yi Xue Za Zhi; 2009 Jul 28; 89(28):1960-3. PubMed ID: 19950569
    [Abstract] [Full Text] [Related]

  • 18. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.
    Wutte A, Plank J, Bodenlenz M, Magnes C, Regittnig W, Sinner F, Rønn B, Zdravkovic M, Pieber TR.
    Exp Clin Endocrinol Diabetes; 2007 Jul 28; 115(7):461-7. PubMed ID: 17647145
    [Abstract] [Full Text] [Related]

  • 19. Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes.
    Home PD, Hallgren P, Usadel KH, Sane T, Faber J, Grill V, Friberg HH.
    Diabetes Res Clin Pract; 2006 Feb 28; 71(2):131-9. PubMed ID: 16054266
    [Abstract] [Full Text] [Related]

  • 20. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial.
    Bartley PC, Bogoev M, Larsen J, Philotheou A.
    Diabet Med; 2008 Apr 28; 25(4):442-9. PubMed ID: 18387078
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.